Guangshengtang announced on the evening of March 31 that the company and Ruitailai signed a “technical service contract” for 10 drugs in March 2022. In addition to ritonavir tablets, clopidogrel bisulfate tablets, and aspirin enteric tablets, this related transaction plans to prematurely terminate the “Technical Service Contract” for the remaining 7 drugs (Ruitailai has prepaid 10% of the total contract amount in accordance with the agreement) and signed a “Termination Agreement”.
广生堂：拟终止部分技术服务合同
Guangshengtang: Plans to terminate some technical service contracts
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.